Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs Type (Top 3 Countries, Chemotherapy Drugs, Pipeline Drugs) - Growth, Future Prospects And Competitive Analysis, 2017 - 2025

Acute myeloid leukemia (AML) is type of blood and bone marrow cancer characterized by abnormal production of myeloid blasts in the bone marrow and peripheral blood. Rising incidence of AML, higher number of unmet needs, expected launch of ideal molecules and technological advances are prime factors that driving the growth of AML therapeutics market globally.

The report titled “Acute Myeloid Leukemia (AML) therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2017–2025” offers strategic insights into the overall AML therapeutics market along with the market size and estimates for the duration 2015 to 2025. The research study covers in-depth analysis of market segments based on drug type (chemotherapy drugs and pipeline drugs) and different geographical regions. Geographically, the global AML therapeutics market is studied for the following regional markets:   

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of MEA

Market size and forecast for these regional and country level markets are presented in this study for the period 2015-2025. Market growth rates for the forecast period 2017-2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global AML therapeutics market. Pipeline analysis and global epidemiology data has been included in report. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global AML therapeutics market. This report concludes with company profiles section that highlights major information about the key players engaged in global AML therapeutics market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report.      

Thus, the research study provides a holistic view of the global AML therapeutics market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.

Acute Myeloid Leukemia (AML) Therapeutics Market

Based on the drug type, the global acute myeloid leukemia (AML) therapeutics market is segmented as follows:

  • Chemotherapy Drugs
    • Cytarabine
    • Anthracyclines
  • Daunorubicin
  • Idarubicin
  • Mitoxantrone
    • Etoposide
    • Other
  • Pipeline Drugs

Acute myeloid leukemia (AML) is a cancer of blood and bone marrow, it is characterized by an overproduction of immature myeloblasts or leukaemic blasts. AML therapeutics market expected to show significant market growth during forecast period primarily due to growing prevalence of leukemia and presence of ideal pipeline molecules. Treatment of AML is typically divided into two phases, induction therapy and post-remission therapy. It is studied that, in the base year 2016, cytarabine was major revenue generating segment due to its effectiveness and hence it is primary component of chemotherapy regimens. It is estimated that newly approved drugs such as gemtuzumab ozogamicin, Vyxeos, midostaurin will show significant market growth during forecast period. It is studied that presence of strong pipeline molecules such as Bosutinib, Vosaroxin, Omacetaxine mepesuccinate, Venetoclax or Quizartinib would assist AML therapeutics market growth during forecast period 2017-2025.

 Acute Myeloid Leukemia (AML) Therapeutics Market

For the purpose of this study, the global acute myeloid leukemia (AML) therapeutics market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Acute Myeloid Leukemia (AML) Therapeutics Market

Acute Myeloid Leukemia (AML) is a type of blood cancer characterized by expansion of myeloid blasts in the bone marrow and peripheral blood. According to GLOBOCAN worldwide prevalence of AML is approximately 1.5% and 1.4% for male and female respectively.  It is observed that currently, North America is dominating AML therapeutics market due to developed healthcare infrastructure, advance technologies, higher number of targeted population, upsurge in funding by government agencies and regulatory approval of newer molecules. Furthermore increase in incidence of AML and upcoming regulatory approval of newer molecules would boost the AML therapeutics market during forecast period. American Cancer Society recorded approximately 21,380 new cases and 10,590 deaths from AML in United States in year 2017. It is estimated that, Asia Pacific will show significant AML therapeutics market growth during forecast period due to developing healthcare infrastructure, increasing incidence of AML and rising treatment awareness.

Choose License Type
Published Date:  Sep 2017
Category:  Pharmaceuticals
Report ID:   58717
Report Format:   PDF
Pages:   120
Rating:    4.3 (50)
Connect With Us
+1-408-641-3282
24/7 Research Support